Michael Alonso

Scientific Co-founder & SVP Research Bolt Biotherapeutics

Michael Alonso, Ph.D., Senior Vice President, Research, is scientific co-founder at Bolt Biotherapeutics and co-inventor of Bolt’s proprietary ISAC platform. Dr. Alonso is passionate about translating scientific discoveries into innovative therapies that ensure cancer patients become cancer survivors. Dr. Alonso brings deep expertise in myeloid biology and drug discovery, with more than a decade of research and translational experience in immunology, neuroscience, and transplant biology. Prior to joining Bolt, Dr. Alonso served as the lead scientist at a Bay Area biotechnology start-up company and held leadership roles at Stanford University.

Dr. Alonso is a well-published scientist who earned his Ph.D. from Stanford University School of Medicine and his Certificate in Entrepreneurship from the Stanford Graduate School of Business. Dr. Alonso graduated with distinction from the University of Illinois at Urbana-Champaign, where he obtained his Bachelor of Science degree in molecular and cellular biology.

Seminars

Thursday 19th March 2026
Enhancing the Therapeutic Window for Oligo Payloads in Cancer
2:30 pm
  • Integrating saRNA and siRNA payloads into antibody conjugates
  • Managing immunogenicity and safety considerations
  • Identifying the next wave of oligonucleotide drug conjugate candidates
Michael Alonso - 5th Novel Conjugates Summit